BCRX BioCryst Pharmaceuticals Inc.

2.67
+0.07  (+3%)
Previous Close 2.6
Open 2.63
Price To Book -9.89
Market Cap 411,337,837
Shares 154,059,115
Volume 5,031,275
Short Ratio
Av. Daily Volume 2,394,879
Stock charts supplied by TradingView

NewsSee all news

  1. BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired

  2. BioCryst Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the completion of an underwritten public offering of 43,620,690 shares of its common stock,

  3. BioCryst to Present at Upcoming Investor Conferences

    RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Jefferies London Healthcare Conference on Thursday,

  4. BioCryst Prices Public Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the pricing of an underwritten public offering of 37,931,035 shares of its common stock,

  5. BioCryst Commences Public Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that it is offering to sell $55 million of its common stock in an underwritten public

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved September 21, 2017.
RAPIVAB (peramivir injection)
Acute uncomplicated influenza to pediatric patients
Phase 3 trial to commence 2020.
BCX7353
Angioedema attacks in patients with hereditary angioedema (HAE)
NDA filing due 4Q 2019.
BCX7353 - APeX-2
Reduce or eliminate attacks in HAE patients
Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Approved Dec 22 2014
RAPIVAB (peramivir)
INFLUENZA ACUTE
Phase 1 trial completion announced May 9, 2019. Generally safe and well tolerated.
Galidesivir
Healthy volunteers
Phase 1 data due 1H 2020.
BCX9930
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1 initiation announced November 1, 2019. Data due 2H 2020.
BCX9250
Fibrodysplasia ossificans progressiva (FOP)

Latest News

  1. BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired

  2. BioCryst Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the completion of an underwritten public offering of 43,620,690 shares of its common stock,

  3. BioCryst to Present at Upcoming Investor Conferences

    RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Jefferies London Healthcare Conference on Thursday,

  4. BioCryst Prices Public Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the pricing of an underwritten public offering of 37,931,035 shares of its common stock,

  5. BioCryst Commences Public Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that it is offering to sell $55 million of its common stock in an underwritten public

  6. Biocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

    RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present two abstracts at the upcoming Annual Scientific Meeting of the

  7. BioCryst Reports Third Quarter 2019 Financial Results and Upcoming Key Milestones

    —New drug application for oral, once-daily BCX7353 for prevention of hereditary angioedema attacks on-track for submission to FDA in Q4 2019— —Data from proof of concept study in PNH patients with oral Factor D

  8. New Clinical Trial Results and Market Research Support Significant Commercial Opportunity for Oral, Once Daily BCX7353 in HAE

    —Results of the APeX-S and APeX-2 trials show patients taking 150 mg of oral, once daily BCX7353 achieved a stable average attack rate of ≤ 1 attack per month at 48 weeks— —75 percent of patients taking 150 mg BCX7353

  9. BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks

    —Agreement includes up to $42 million of upfront and potential milestone payments plus royalties on net sales— —JNDA submission to PMDA on track for Q1 2020— —Deal leverages Torii's proven track record to deliver

  10. BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired

  11. BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva

    —BCX9250 significantly suppressed heterotrophic ossification in preclinical studies— —Urgent medical need with no approved treatments for FOP — —Phase 1 data expected in 2H 2020— RESEARCH TRIANGLE PARK, N.C., Nov.

  12. BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients

    —Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— —Part 1 SAD and part 2 MAD data

  13. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired

  14. U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile

    RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to

  15. BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Global Healthcare Conference in New York on

  16. BioCryst Appoints Helen Thackray, M.D., to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed clinical rare disease expert, Helen Thackray, M.D., FAAP, to

  17. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired

  18. BioCryst to Present at H.C. Wainwright Global Investment Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the H.C. Wainwright Global Investment Conference in New